Publication | Closed Access

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Clinical TherapeuticAdvanced Squamous NsclcMedicinePharmacologyClinical TrialsPhase Iii TrialFirst-line TreatmentPharmacotherapyCancer TreatmentDrug TrialOncologyNovel Therapy